BioAge Labs (BIOA) Common Equity (2023 - 2026)

BioAge Labs has disclosed Common Equity across 4 years of filings, most recently posting $379.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at $379.1 million, up 21.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $379.1 million (up 21.06% YoY), and the FY2025 annual result was $272.1 million, down 15.81% from the prior year.
• Common Equity came in at $379.1 million for Q1 2026 at BioAge Labs, up from $272.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $379.1 million in Q1 2026 to a low of -$197.1 million in Q2 2024.
• The 4-year median for Common Equity is $277.5 million (2025), against an average of $133.1 million.
• Across the five-year window, Common Equity jumped 304.88% in 2024 and retreated 15.81% in 2025, its largest moves.
• BioAge Labs' Common Equity stood at -$173.4 million in 2023, then soared by 286.35% to $323.1 million in 2024, then decreased by 15.81% to $272.1 million in 2025, then soared by 39.36% to $379.1 million in 2026.
• The last three Common Equity figures came in at $379.1 million (Q1 2026), $272.1 million (Q4 2025), and $277.5 million (Q3 2025), per Business Quant data.